Analyst Price Targets — CAH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 8, 2026 1:11 pm | Elizabeth Anderson | Evercore ISI | $240.00 | $215.13 | TheFly | Cardinal Health price target lowered to $240 from $260 at Evercore ISI |
| March 9, 2026 5:22 pm | Michael Cherny | Leerink Partners | $275.00 | $222.28 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Cardinal Health (CAH): "company is set up for solid FY2H'26 growth" |
| February 24, 2026 10:22 am | — | Barclays | $258.00 | $224.82 | TheFly | Cardinal Health price target raised to $258 from $243 at Barclays |
| February 10, 2026 11:36 am | — | Wells Fargo | $256.00 | $225.76 | TheFly | Cardinal Health price target raised to $256 from $237 at Wells Fargo |
| February 6, 2026 3:43 pm | — | Morgan Stanley | $255.00 | $229.63 | TheFly | Cardinal Health price target raised to $255 from $245 at Morgan Stanley |
| February 6, 2026 2:43 pm | — | Robert W. Baird | $252.00 | $228.78 | TheFly | Cardinal Health price target raised to $252 from $250 at Baird |
| February 6, 2026 1:14 pm | Kevin Caliendo | UBS | $260.00 | $228.63 | TheFly | Cardinal Health price target raised to $260 from $250 at UBS |
| February 6, 2026 12:33 pm | Steven Valiquette | Mizuho Securities | $235.00 | $227.18 | TheFly | Cardinal Health price target raised to $235 from $222 at Mizuho |
| February 5, 2026 7:21 pm | Elizabeth Anderson | Evercore ISI | $260.00 | $227.18 | StreetInsider | Cardinal Health (CAH) PT Raised to $260 at Evercore ISI |
| January 29, 2026 12:20 pm | Erin Wright | Morgan Stanley | $245.00 | $210.39 | TheFly | Cardinal Health price target raised to $245 from $224 at Morgan Stanley |
Latest News for CAH
In the latest trading session, Cardinal Health (CAH) closed at $211.83, marking a -1.45% move from the previous day.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Research confirms advanced therapies are moving beyond inpatient hospitals, with providers increasingly supporting partnerships that bring life-changing treatments closer to patients' homes. DUBLIN, Ohio, April 14, 2026 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2026 Advanced Therapies Report: Perspectives on Community Expansion, offering new insights into how the expanding advanced therapy…
CAH's specialty growth, strong pharma demand and expanding services portfolio are driving earnings momentum and positioning it for sustained long-term growth.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.